Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 15/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | PLAU | P00749 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23425262 | 0.86 | PTPN11 (0.51) | PTPN11KCNH2EGFRCHRM4PLAU | |
| SCHEMBL24233691 | 0.82 | PTPN11 (0.50) | PTPN11KCNH2EGFRPDCD1LG2CD274 | |
| SCHEMBL24233675 | 0.81 | PTPN11 (0.71) | PTPN11KCNH2EGFRPDCD1LG2CD274 | |
| SCHEMBL25514430 | 0.81 | PTPN11 (0.48) | PTPN11KCNH2EGFRCHRM4 | |
| SCHEMBL24282660 | 0.81 | PTPN11 (0.50) | PTPN11KCNH2EGFRCHRM4PLAU | |
| SCHEMBL19785445 | 0.80 | PTPN11 (0.52) | PTPN11KCNH2EGFR | |
| SCHEMBL21115041 | 0.80 | PTPN11 (0.52) | PTPN11KCNH2EGFR | |
| SCHEMBL24233630 | 0.80 | PTPN11 (0.58) | PTPN11KCNH2EGFRPDCD1LG2CD274 | |
| SCHEMBL24233624 | 0.80 | PTPN11 (0.43) | PTPN11KCNH2EGFRCYP11B1CYP11B2 | |
| SCHEMBL24233642 | 0.80 | PTPN11 (0.51) | PTPN11KCNH2EGFRCYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220031695-A1 | SHP2 INHIBITOR COMPOSITIONS FOR USE IN TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220031695-A1 | SHP2 INHIBITOR COMPOSITIONS FOR USE IN TREATING CANCER | PTPN18, PTPN7, PTPN1 | PTPN11 14/4885KCNH2 4775/4885EGFR 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.